Análisis Argos
CHE
CHEEn su precio
Chemed Corporation · Healthcare
US$ 489.66
precio al 2026-07-04
Valor justo Argos*
US$ 366–461
vs. su valor justo
19% por encima
Score Argos
74/100
En su precio
LA RESPUESTA
El precio asume un crecimiento (9.8%) en línea con lo que la empresa demuestra (10.3%). Ni ganga ni exceso — el mercado le puso un precio razonable.
Recompensas
Cotiza 23% por debajo de su valor justo.
Retorno sobre el capital alto (24%).
Riesgos
!Crecimiento estancado o en baja.
VALOR3/6FUTURO2/6PASADO4/6SALUD6/6DIVIDENDO5/6
El Iris de calidad
VALOR3/6FUTURO2/6PASADO4/6SALUD6/6DIVIDENDO5/6
ValorCerca de su valor justo
FuturoCrecimiento moderado
PasadoFundamentales sólidos y sostenidos
SaludBalance fuerte, deuda controlada
DividendoDevuelve capital al accionista
Score Argos74de 100En su precio
Ingresos4%
US$ 2.5 B
Margen operativo11%
13.4%
Flujo de caja libre11%
US$ 0.3 B
Deuda neta
US$ 0.1 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 6.5B
P/E24.5x
EV/EBITDA16.3x
FCF yield5%
ROIC23.8%
Margen operativo13.4%
Crecim. ingresos+4.1%/año
Piotroski F6/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

globenewswire.com · 1 jul
Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29
CINCINNATI, July 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2026, on Tuesday, July 28, 2026, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m.
zacks.com · 26 jun
Should You Hold Chemed Stock in Your Portfolio Now?
CHE's VITAS growth and Roto-Rooter improvements support its outlook, but inflation, tariffs and competitive pressures remain key risks.
zacks.com · 10 jun
AVAH or CHE: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Aveanna Healthcare (AVAH) and Chemed (CHE). But which of these two stocks presents investors with the better value opportunity right now?
globenewswire.com · 8 jun
Roto-Rooter Buys Franchise Territory in Corpus Christi, Rio Grande Valley, and Beaumont, Texas
CINCINNATI, June 08, 2026 (GLOBE NEWSWIRE) -- Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation ("Chemed") (NYSE: CHE) announced it has acquired a formerly independent Roto-Rooter franchise serving 21 counties in south Texas for approximately $12.0 million. The service area includes the cities of Corpus Christi, McAllen, Laredo and Brownsville, Texas.
zacks.com · 25 may
AVAH vs. CHE: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Aveanna Healthcare (AVAH) or Chemed (CHE). But which of these two stocks is more attractive to value investors?
seekingalpha.com · 20 may
Chemed Corporation (CHE) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Chemed Corporation (CHE) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
globenewswire.com · 18 may
Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend
CINCINNATI, May 18, 2026 (GLOBE NEWSWIRE) -- Stockholders of Chemed Corporation (NYSE: CHE) today elected a slate of nine directors at the Company's 2026 annual stockholders' meeting. Stockholders ratified the continuation of PricewaterhouseCoopers LLP as the Company's independent accountants for 2026.
globenewswire.com · 18 may
Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend
CINCINNATI, May 18, 2026 (GLOBE NEWSWIRE) -- Stockholders of Chemed Corporation (NYSE: CHE) today elected a slate of nine directors at the Company's 2026 annual stockholders' meeting.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.